

ESPS PEER-REVIEW REPORT

Name of journal: World Journal of Gastrointestinal Pharmacology and Therapeutics

ESPS manuscript NO: 19783

Title: DAA treatment of decompensated hepatitis C virus-induced liver cirrhosis

Reviewer's code: 00503443

Reviewer's country: Italy

Science editor: Fang-Fang Ji

Date sent for review: 2015-05-21 16:39

Date reviewed: 2015-06-01 18:54

CLASSIFICATION	LANGUAGE EVALUATION	SCIENTIFIC MISCONDUCT	CONCLUSION
<input type="checkbox"/> Grade A: Excellent	<input type="checkbox"/> Grade A: Priority publishing	Google Search:	<input type="checkbox"/> Accept
<input checked="" type="checkbox"/> Grade B: Very good	<input checked="" type="checkbox"/> Grade B: Minor language polishing	<input type="checkbox"/> The same title	<input type="checkbox"/> High priority for publication
<input type="checkbox"/> Grade C: Good		<input type="checkbox"/> Duplicate publication	
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade C: A great deal of language polishing	<input type="checkbox"/> Plagiarism	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade E: Poor	<input type="checkbox"/> Grade D: Rejected	<input checked="" type="checkbox"/> No	<input checked="" type="checkbox"/> Minor revision
		BPG Search:	<input type="checkbox"/> Major revision
		<input type="checkbox"/> The same title	
		<input type="checkbox"/> Duplicate publication	
		<input type="checkbox"/> Plagiarism	
		<input checked="" type="checkbox"/> No	

COMMENTS TO AUTHORS

The work of Shogo Ohkoshi et al entitled: DAA treatment of decompensated HCV-induced liver cirrhosis, is a review of the current literature about the new treatments of hepatitis C virus related liver diseases. This is an actual topic with high interest for hepatologists, who see in these new treatments the definite cure for HCV infection. The authors review the natural history of HCV infection, the past treatment based mainly on IFN therapy and the recent progress reached with the introduction of the DAA (direct acting antiviral) therapy. Findings of these new treatments are reviewed for patients with compensated LC, decompensated LC and patients with co-morbidities, focusing on the high SVR rate reached by these treatments but also the possible risks in treating decompensated as well as patients with co-morbidities. The work is well written and well balanced in the various sections and in the opinion of this reviewer the paper is suitable for publication in World Journal of Gastrointestinal Pharmacology and Therapeutics. However some little corrections are needed. Page 6, line 9: commodities is perhaps comorbidities? Page 6, line 16: "... use of NAs for .." NAs is perhaps DAAs? Page 8, line 7: strong a antiviral "a" is to be deleted Page 8, line 15: teraprevir is perhaps Telaprevir? Page 10, line 9: "dasabuvir plus and RBV-based ..." "plus



BAISHIDENG PUBLISHING GROUP INC

8226 Regency Drive, Pleasanton, CA 94588, USA

Telephone: +1-925-223-8242

Fax: +1-925-223-8243

E-mail: bpgoffice@wjgnet.com

<http://www.wjgnet.com>

and", please make correction Page 10, line 12: Patents is perhaps Patients? Page 17, last word: complications. It would be better to substitute him with comorbidities Also the English style needs to be revised by an english native speaker